Abstract:Abstract Funding Acknowledgements Type of funding sources: None. Background A polygenic risk score (PRS) is derived from a genome-wide association study (GWAS) and represents an aggregate of thousands of single-nucleotide polymorphisms (SNPs) that provide a baseline estimate of an individual’s genetic risk for a specific disease or trait at birth. Cardiometabolic disease represents a set of disease processes that historically have disproportionally affected underrepresented racial and minority groups. Furthermore, these groups represent a population generally not well captured by traditional risk scores compared to European cohorts. Since the first GWAS studying myocardial infarction was published, PRSs have increasingly been seen as a promising tool to improve risk stratification of non-European populations. However, how PRSs can be best used in clinical practice remains unclear. Purpose To provide an overview of the PRSs related to cardiometabolic disease, analyze the ancestral diversity of GWAS cohorts, and discuss the evidence supporting their clinical applications. Methods The Preferred Reporting Items For Systematic Reviews and Meta-analysis extension for Scoping Reviews protocol was used to conduct a scoping review of the MEDLINE, EMBASE, and CENTRAL databases. English studies that published a PRS related to atrial fibrillation (AF), cerebrovascular disease (CVD), coronary artery disease (CAD), dyslipidemia, heart failure, heritable cardiomyopathy, hypertension, and type 2 diabetes were reviewed. Results Across the 4,863 studies screened, 82 articles met the inclusion criteria. The most common PRS related to CAD, followed by hypertension and CVD. Limited ancestral diversity was observed as most studies (56) included only individuals of European ancestry. A smaller proportion of studies (16) published PRSs derived in multi-ancestry cohorts. Only ten studies published a PRS derived solely from a sample population of non-European ancestry (Chinese, East Asian, Japanese, and Korean). The predictive performance of most PRSs was similar to or superior to traditional risk factors. More than half of the included studies (42) reported an integrated risk model combining a PRS with traditional risk factors or a clinical risk tool (FRS, PCE, CHADS2). The integrated risk model consistently improved predictive accuracy, but few studies investigated the performance in a non-European population. Conclusion In conclusion, this scoping review is the first of its kind and reports strong evidence for the clinical use of PRSs in AF, CAD, CVD, and hypertension. However, most PRSs are derived in cohorts of European ancestry, which contributes to a lack of PRS transferability across different ancestral groups, likely exacerbating health inequities. Future prospective studies should focus on further establishing the clinical utility of PRSs. Additionally, diversity in future GWAS cohorts is essential to ensure that PRSs reflect the multi-ancestry society at large.

Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management

Prevalence of Pragmatically Defined High CV Risk and its Correlates in LMIC: A Report From 10 LMIC Areas in Africa, Asia, and South America.

Associations of Polysocial Risk Score, Lifestyle and Genetic Factors with Incident Type 2 Diabetes: a Prospective Cohort Study

Polygenic risk scores for the prediction of cardiometabolic disease

A critique and examination of the polysocial risk score approach: predicting cognition in the Health and Retirement Study

Current State and Future of Polygenic Risk Scores in Cardiometabolic Disease: A Scoping Review

Abstract P339: The Clinical Application and Ancestral Diversity of Cardiometabolic Polygenic Risk Scores

Polysocial and Polygenic Risk Scores and All-Cause Dementia, Alzheimer's Disease, and Vascular Dementia.

The current state and future of cardiometabolic polygenic risk scores in European and non-European population cohorts

Polygenic Risk Scores: The Next Step for Improved Risk Stratification in Coronary Artery Disease?

Invited Commentary: Is the Polysocial Score Approach Valuable for Advancing Social Determinants of Health Research?

Race, Racism, and Risk—Implications of Social Determinants of Health in Cardiovascular Disease Prediction

A Fair Individualized Polysocial Risk Score for Identifying Increased Social Risk in Type 2 Diabetes

Developing A Fair Individualized Polysocial Risk Score (iPsRS) for Identifying Increased Social Risk of Hospitalizations in Patients with Type 2 Diabetes (T2D)

Polygenic risk scores: from research tools to clinical instruments

Psychosis Polyrisk Score (PPS) for the Detection of Individuals At-Risk and the Prediction of Their Outcomes

Social Phenotyping for Cardiovascular Risk Stratification in Electronic Health Registries

166-OR: Developing a Fair Individualized Polysocial Risk Score (iPsRS) for Identifying Increased Social Risk of Hospitalizations in Patients with Type 2 Diabetes (T2D)

Polygenic Risk Score to Identify Subclinical Coronary Heart Disease Risk in Young Adults

Population Performance and Individual Agreement of Coronary Artery Disease Polygenic Risk Scores

Polygenic Risk Scores in Predicting Coronary Artery Disease in Symptomatic Patients. A Validation Study